Dentsply Sirona INC 8-K filings

DENTSPLY SIRONA Inc. filed an amendment to its Form 8-K to correct an EDGAR description tag, confirming its second quarter 2026 financial results and reiterating its full-year outlook.

Dentsply Sirona announced second quarter 2026 financial results, reporting net sales of $898 million and adjusted EPS of $0.52, meeting expectations and reiterating its full-year outlook.

Dentsply Sirona announced the appointment of John Fortson as its new Executive Vice President and Chief Financial Officer, effective July 20, 2026.

DENTSPLY SIRONA Inc. reports the successful election of twelve directors and approval of key incentive plans at its 2026 Annual Meeting.

DENTSPLY SIRONA Inc. announced its first fiscal quarter 2026 financial results, reporting net sales of $880 million and reiterating its full-year outlook.

Dentsply Sirona announced Q4 2025 net sales growth and adjusted EPS, alongside a restructuring plan, dividend elimination, and a 2026 outlook.

Dentsply Sirona expands its Board of Directors with two new financial and operational experts to enhance strategic oversight for its Return-to-Growth plan.

Dentsply Sirona and Patterson Dental have renewed their U.S. dental technology distribution agreement, aiming to accelerate growth and expand access to integrated solutions.

Dentsply Sirona appointed Donald Zurbay to its Board of Directors and established a new Growth and Value Creation Committee to oversee its Return-to-Growth action plan.

DENTSPLY SIRONA Inc. has amended its credit and note purchase agreements, significantly loosening leverage covenants and modifying EBITDA calculations, while introducing interest rate step-ups for higher leverage.

DENTSPLY SIRONA Inc. announced the appointment of Michael Pomeroy as interim Chief Financial Officer, effective November 25, 2025, while the search for a permanent CFO continues.

DENTSPLY SIRONA Inc. filed an amendment to its 8-K, detailing the separation agreement with former Executive Vice President and CFO Matthew E. Garth, including severance payments and equity treatment.

Dentsply Sirona reported a 5.0% net sales decrease in Q3 2025, announced a new 'Return-to-Growth' action plan, and revised its full-year outlook downwards.

DENTSPLY SIRONA Inc. announced the departure of its Executive Vice President and Chief Financial Officer, Matthew E. Garth, effective November 5, 2025, with CEO Daniel T. Scavilla assuming interim principal financial officer duties.

DENTSPLY SIRONA Inc. announced the SEC has concluded its investigation into financial reporting matters without recommending enforcement action.

DENTSPLY SIRONA Inc. announced that Executive Vice President Richard C. Rosenzweig will transition from his current role to Special Legal Advisor, effective October 3, 2025.

DENTSPLY SIRONA Inc. approved a $2 million retention equity award for its Chief Supply Chain Officer, Tony Johnson, to ensure his continued employment for three years.

Dentsply Sirona announced it will retain its Wellspect Healthcare business after a comprehensive strategic review, citing greater long-term value for stockholders.

Dentsply Sirona reported a net loss of $45 million in Q2 2025, driven by a 4.9% sales decrease and a significant goodwill impairment, despite improvements in adjusted margins.

Dentsply Sirona announced the appointment of Daniel Scavilla as its new President and CEO, effective August 1, 2025, succeeding Simon Campion, while also providing preliminary second-quarter 2025 financial results and reaffirming its full-year outlook.

DENTSPLY SIRONA Inc. announced the successful issuance of $550 million in 8.375% junior subordinated notes due 2055, utilizing a portion of the proceeds to fully repay its $435 million bridge loan facility without incurring penalties.

Dentsply Sirona Inc. announced the pricing of its $550 million aggregate principal amount of 8.375% Fixed-to-Fixed Reset Rate Junior Subordinated Notes due 2055, with proceeds intended for general corporate purposes including debt repayment.

DENTSPLY SIRONA Inc. has secured amendments to its revolving credit facility and note purchase agreements, adjusting key financial covenants and introducing interest rate step-ups tied to credit ratings, while also completing a significant subordinated debt issuance.

Dentsply Sirona Inc. has announced the appointment of Matthew E. Garth, a seasoned financial executive with nearly 30 years of experience, as its new Executive Vice President and Chief Financial Officer, effective May 30, 2025.

DENTSPLY SIRONA Inc. held its annual meeting of stockholders on May 21, 2025, and announced the results of voting on key proposals, including the election of directors, ratification of the appointment of independent auditors, approval of executive compensation, and an amendment to the Omnibus Incentive Plan.

Dentsply Sirona's Q1 2025 results show a decrease in net sales but an expansion in adjusted EBITDA margin, with the company maintaining its FY25 outlook for organic sales and adjusted EPS.

DENTSPLY SIRONA Inc. has entered into a $435 million bridge loan agreement to repay commercial paper borrowings and for general corporate purposes.

Dentsply Sirona's 2024 results reveal a net loss and sales decline, with a cautious outlook for 2025 anticipating further organic sales decrease.

Dentsply Sirona has initiated a process to evaluate strategic alternatives for its Wellspect Healthcare business, a leading provider of bladder and bowel management care products.

Dentsply Sirona appoints Michael Barber and Daniel Scavilla to its Board of Directors and announces the resignation of Dr. Dorothea Wenzel, effective February 5, 2025.